Jindani, A <br/><br/>
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.  [electronic resource] 

 -  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease  06 2016 
 - 832-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1815-7920 
<br/><br/><label>Standard No.: </label>10.5588/ijtld.15.0577  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antitubercular Agents--therapeutic use<br/>Dose-Response Relationship, Drug<br/>Ethambutol--therapeutic use<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Isoniazid--therapeutic use<br/>Male<br/>Middle Aged<br/>Patient Compliance<br/>Pyrazinamide--therapeutic use<br/>Rifampin--therapeutic use<br/>Treatment Outcome<br/>Tuberculosis, Pulmonary--drug therapy<br/>Young Adult